JP6620338B2 - 低用量ナルトレキソンによるがん細胞の準備刺激 - Google Patents

低用量ナルトレキソンによるがん細胞の準備刺激 Download PDF

Info

Publication number
JP6620338B2
JP6620338B2 JP2016572543A JP2016572543A JP6620338B2 JP 6620338 B2 JP6620338 B2 JP 6620338B2 JP 2016572543 A JP2016572543 A JP 2016572543A JP 2016572543 A JP2016572543 A JP 2016572543A JP 6620338 B2 JP6620338 B2 JP 6620338B2
Authority
JP
Japan
Prior art keywords
naltrexone
cancer
small molecule
inhibitor
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2016572543A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017519006A (ja
JP2017519006A5 (enExample
Inventor
ダルグリッシュ，アンガス
リウ，ワイ
Original Assignee
エルディーエヌ ファーマ リミテッド
エルディーエヌ ファーマ リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by エルディーエヌ ファーマ リミテッド, エルディーエヌ ファーマ リミテッド filed Critical エルディーエヌ ファーマ リミテッド
Publication of JP2017519006A publication Critical patent/JP2017519006A/ja
Publication of JP2017519006A5 publication Critical patent/JP2017519006A5/ja
Application granted granted Critical
Publication of JP6620338B2 publication Critical patent/JP6620338B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/664—Amides of phosphorus acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4703—Regulators; Modulating activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2510/00—Detection of programmed cell death, i.e. apoptosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Pathology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2016572543A 2014-06-09 2015-06-09 低用量ナルトレキソンによるがん細胞の準備刺激 Active JP6620338B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1410216.4A GB201410216D0 (en) 2014-06-09 2014-06-09 Therapeutic
GB1410216.4 2014-06-09
PCT/GB2015/051686 WO2015189597A1 (en) 2014-06-09 2015-06-09 Priming of cancer cells with low dose naltrexone

Publications (3)

Publication Number Publication Date
JP2017519006A JP2017519006A (ja) 2017-07-13
JP2017519006A5 JP2017519006A5 (enExample) 2018-07-05
JP6620338B2 true JP6620338B2 (ja) 2019-12-18

Family

ID=51266919

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016572543A Active JP6620338B2 (ja) 2014-06-09 2015-06-09 低用量ナルトレキソンによるがん細胞の準備刺激

Country Status (10)

Country Link
US (3) US11065245B2 (enExample)
EP (1) EP3151831B1 (enExample)
JP (1) JP6620338B2 (enExample)
DK (1) DK3151831T3 (enExample)
ES (1) ES2730348T3 (enExample)
GB (1) GB201410216D0 (enExample)
PL (1) PL3151831T3 (enExample)
PT (1) PT3151831T (enExample)
TR (1) TR201908660T4 (enExample)
WO (1) WO2015189597A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201308440D0 (en) * 2013-05-10 2013-06-19 Dalgleish Angus Therapeutic
EP3416619A2 (en) * 2016-02-18 2018-12-26 Immune Therapeutics, Inc. Method for inducing a sustained immune response
GB201704913D0 (en) * 2017-03-28 2017-05-10 Ldn Pharma Ltd Method
GB201704911D0 (en) * 2017-03-28 2017-05-10 Ldn Pharma Ltd High dose combo I
GB201704909D0 (en) 2017-03-28 2017-05-10 Ldn Pharma Ltd Cancer therapy
EP3482751A1 (en) 2017-11-14 2019-05-15 LDN Pharma Limited Cancer treatment
EP3934647A1 (en) * 2019-03-06 2022-01-12 LDN Pharma Limited Method for determining efficacy
GB201903546D0 (en) * 2019-03-15 2019-05-01 Ldn Pharma Ltd Cancer treatment
CN114364402A (zh) 2019-07-15 2022-04-15 罗瓦萨公司 用于治疗癌症的阿片类生长因子受体(ogfr)拮抗剂，特别是纳洛酮和/或纳曲酮

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030144312A1 (en) * 2001-10-30 2003-07-31 Schoenhard Grant L. Inhibitors of ABC drug transporters in multidrug resistant cancer cells
AU2009225434B2 (en) 2008-03-21 2014-05-22 The University Of Chicago Treatment with opioid antagonists and mTOR inhibitors
JP2015107918A (ja) 2012-02-14 2015-06-11 国立研究開発法人国立がん研究センター 抗がん剤の作用を増強する医薬組成物、がん治療用キット、診断薬、及びスクリーニング方法
GB201308440D0 (en) * 2013-05-10 2013-06-19 Dalgleish Angus Therapeutic

Also Published As

Publication number Publication date
JP2017519006A (ja) 2017-07-13
GB201410216D0 (en) 2014-07-23
EP3151831B1 (en) 2019-03-13
US20250032481A1 (en) 2025-01-30
US11065245B2 (en) 2021-07-20
DK3151831T3 (da) 2019-06-24
ES2730348T3 (es) 2019-11-11
PT3151831T (pt) 2019-06-18
PL3151831T3 (pl) 2021-05-31
US20210308125A1 (en) 2021-10-07
EP3151831A1 (en) 2017-04-12
WO2015189597A1 (en) 2015-12-17
US12144807B2 (en) 2024-11-19
TR201908660T4 (en) 2019-07-22
US20170119755A1 (en) 2017-05-04

Similar Documents

Publication Publication Date Title
JP6620338B2 (ja) 低用量ナルトレキソンによるがん細胞の準備刺激
ES2863996T3 (es) Terapia de combinación para el tratamiento del cáncer
Fukushiro-Lopes et al. Preclinical study of a Kv11. 1 potassium channel activator as antineoplastic approach for breast cancer
BR112013028095B1 (pt) Uso de inibidores de csf-1r para o tratamento de tumores cerebrais
WO2014092905A1 (en) Methods and assays for combination treatment of cancer
JP7442439B2 (ja) Ｋｄｍ４阻害剤
US20240398804A1 (en) Methods of treating cancer having an active wnt/beta-catenin pathway
WO2018138510A1 (en) Mebendazole for use in the treatment of cancer
US10206920B2 (en) Pharmaceutical composition for treating cancer and a method of using the same
US20250041245A1 (en) Endoxifen for treatment of cancers
JP2021502982A (ja) 癌治療
JP2020512408A (ja) 肺がんの治療に使用するための組み合わせ
US9566334B2 (en) Combinations of a PI3K/AKT inhibitor compound with an HER3/EGFR inhibitor compound and use thereof in the treatment of a hyperproliferative disorder
CN109982700A (zh) 具有外显子14跳跃突变或外显子14跳跃表型的癌症的治疗
KR20240001703A (ko) 유비퀴틴 특이적 펩티다제 22 (usp22)의 억제제 및 질환 및 장애를 치료하기 위한 그의 용도
US20240398814A1 (en) Kras inhibitor and hdac inhibitor combination for the treatment of cancer
US10398672B2 (en) Methods and compositions for targeting cancer stem cells
CN109813913B (zh) 芳烃受体(AhR)在预测免疫治疗效果中的应用
CN111050801B (zh) 用于治疗癌症的增加bcl2-相关的细胞死亡激动剂表达的药剂
Sari Characterization of the anticancer activities of some natural and synthetic compounds: molecular targets and mechanism
JP2025523114A (ja) Ａｔリッチ相互作用ドメイン含有タンパク質１ａ（ａｒｉｄ１ａ）突然変異癌を処置するためのｅｚｈ２阻害療法
Jiang et al. P3. 02-083 DKK1 Promotes Migration and Invasion of Non-Small Cell Lung Cancer via β-Catenin Signaling Pathway
NZ716668B2 (en) Cancer treatment

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180525

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180525

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190423

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190723

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20190827

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190925

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20191028

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20191028

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20191029

R150 Certificate of patent or registration of utility model

Ref document number: 6620338

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250